Essential medicines

Last updated


Essential medicines, as defined by the World Health Organization (WHO), are medicines that "satisfy the priority health care needs of the population". [1] Essential medicines should be accessible to people at all times, in sufficient amounts, and be generally affordable. [2] Since 1977, the WHO has published a model list of essential medicines, with the 2019 list for adult patients containing over 400 medicines. [3] Since 2007, a separate list of medicines intended for child patients has been published. [4] A new list was published in 2021, for both adults and children. [5]

Contents

Several changes have been implemented since the 2021 edition, including that medication cost should not be grounds for exclusion criteria if it meets other selection criteria, and cost-effectiveness differences should be evaluated within therapeutic areas. The following year, antiretroviral agents, usually used in the treatment of HIV/AIDS, were included on the list of essential medicines. [6]

The WHO distinguishes between "core list" and "complementary list" medications.

This list forms the basis of the national drugs policy in more than 155 countries, both in the developed and developing world. Many governments refer to WHO recommendations when making decisions on health spending. Countries are encouraged to prepare their own lists considering local priorities. Over 150 countries have published an official essential medicines list. [7] Despite these efforts, an estimated 2 billion people still lack access to essential medicines, with some of the major obstacles being low supply, including shortages of inexpensive drugs. Following these shortages, the US Food and Drug Administration (FDA) released a report in fall of 2019 with strategies to overcome and mitigate supply issues. [8]

Theory and practice

The original WHO definition in 1977 was that they were medicines "of utmost importance, basic, indispensable, and necessary for the healthcare needs of the population". [9] The concept was mentioned in one of the ten points of the 1978 Alma Ata Declaration on primary health care.

In 2002 the definition was changed to:

Essential medicines are those that satisfy the priority health care needs of the population. [10]

This remains the definition as of 2019. [1]

The use of essential medicines lists has resulted in better quality of care and improved management of health resources in the most cost-effective manner. The lists serve as a baseline for health insurance entities to include or exclude the medication, and modify the dose based on clinical study evidence. To improve the accessibility of essential medicines for both children and adults, it is necessary to ensure the rational use of medicine while also being cost-effective. [11]

In a 2023 study evaluating the availability, distribution, and progress of essential medicines in China, results showed that access to essential medicines is lower in comparison to the WHO's goal, with little progress in expansion over the years. This systematic review and meta-analysis study pooled studies that reported the availability of essential medicines in various regions of China from 2009 to 2019. [12] The data supports the need to improve the access and distribution of medication across regions to ensure that the goal of universal health coverage is reached. [12] Having essential medications be accessible to everyone is the foundation to a better health without financial hardships for the general public. [13]

The goal of universal health coverage was set in place in 2015, where multiple countries have taken steps towards ensuring treatment, palliation, rehabilitation, and preventative health measures for everyone. [13] Understanding that accessibility to appropriate and applicable essential medications within the region, is the first step towards reaching equitable and universal healthcare. [13]

Selection

Items are chosen as essential medicines based on how common the disease that is being treated, evidence of benefit, the degree of side effects and the cost compared to other options. [14] In order to explore the human rights law and WHO's essential medicines policies into national legislation regarding medicines, affordability and financing needs to be understood to enhance universal access to essential medicines. [15] The intention of essential medicine lists is to provide appropriate use of treatment and not include medications that have been withdrawn from the market in other countries due to unfavorable benefit-to-harm balance. [16] Despite many efforts from different countries, some individuals do not have their needs met and have to turn to an alternative plan called the judiciary in order to receive the medications required. The Judiciary also known as the "Judicialization of access to medicines," this involves technical, scientific, legal, and social aspects. Further research is needed to explore these aspects comprehensively. [17]

Cost-to-benefit ratio

Medications can be priced differently, due to the fact that each medication can have many qualities and uses. Because various medicines have different costs, individual uses, and distinct advantages, it prompts the theory of cost effectiveness. [18] Cost effectiveness is the subject of debate between producers (pharmaceutical companies) and purchasers of drugs (national health services). It is estimated that access to essential medicines could save 10 million people a year. [19] Access to essential medicine is a cornerstone of effective healthcare systems and a fundamental component of global health initiatives aimed at improving quality of life, reducing health disparities, and fostering sustainable development. [20] Proper access to essential medicine can lower the amount for really expensive treatments and hospitalizations by managing early and effectively.

History

The WHO made the Model List of Essential Medicines in 1977 based on the idea that certain medicines are required more often than others and are often inaccessible to many different populations. [21] As of 2018, 146 countries are using the Essential Medicines concept, which is also used to guide the reimbursement of medicines depending on the importance to public health, the efficacy, the safety, and the cost of the medicines. [22] The goal of the Essential Medicine concept is that medicines that have the highest relevance in public health, meaning medicines that are used the most often, should be available equally to everyone in a population either for free or at a very affordable cost. [22]

The WHO Model List of Essential Medicines has been updated every two years since 1977. The 23rd version was published in July 2023. [23] Over that period, the number of medications has more than doubled, from the original 208 in 1977, [7] to more than 500 in 2023. [23] Medicines are then categorized as essential or non-essential based on their inclusion in each country's EML. results are then analyzed by WHO regions, World Bank income groups, wealth inequality, and therapeutic groups. The group for essential medicines availability was higher (61.5%) than non-essential medicines (27.3%). But in the public sector, the median availability was 40% for essential medicines, compared to 6.6% for non-essential medicines. Thus, overall, the availability of essential medicines in the public sector is still suboptimal, indicating challenges in achieving equitable access. [24]

Children's list

The first edition of the "WHO Model List of Essential Medicines for Children", was published in 2007, while the 9th edition was published in 2023. [7] [4] [23] It was created to make sure that the needs of children were systematically considered such as availability of proper formulations. [7] While the EML (Essential Medicine List) is intended for the population as a whole, the EMLc (Essential Medicine List for Children) is intended for children up to 12 years old. [25] The first edition contained 450 formulations of 200 different medications [7] and the 2023 list contains 361 medications. [23] The intention of creating an EML for children is to improve child survival and provide treatment options for mortality and morbidity causes. [26]

WHO launched a "Make Medicines Child Size" (MMCS) campaign in 2007 with the purpose of creating appropriate regimens and formulations for children based on their weight and age. [27] A 2021 study assessing the age-appropriateness of enteral formulations listed on the WHO Essential Medicine List for Children (EMLc) highlighted the dependence on factors such as dose adaptability, formulation flexibility, and the child's swallowing ability. Analysis of the EMLc between 2011 and 2019 revealed that most enteral medications were not age-appropriate for children under six years old, necessitating manipulation of the medicine prior to administration. This practice raises concerns regarding safety and efficacy. Consequently, the study emphasizes the urgent need for more comprehensive information and guidelines for selecting and developing age-appropriate essential enteral medicines for pediatric populations. [28]

While the practice of maintaining separate lists for the general population and children under 12 years of age is beneficial in tailoring healthcare interventions, it inadvertently excludes adolescents from the latter category. This age-based cutoff may lead to an oversight of the unique healthcare needs of this demographic. [25] It would be a good idea to create a list for adolescents as well. This is important as it allows healthcare providers to offer tailored care for each group. This differentiation ensures that treatments are appropriate for children's unique physiological needs.

Adult's List

The first EML was published in 1977 and was created as a tool to improve the accessibility and availability of medications for everyone. Multiple editions of EMLs and studies since then have been released, comparing the necessity, efficacy, safety, and of certain medications on the list. [29] In addition, studies have been done comparing EMLs from multiple regions to ensure the appropriateness of dosing and safety of drug classes. [29]

Medication like Codeine has a potential of drug abuse and was established as an essential medication, yet raised some ethical questions. With the lack of literature highlighting its safety, it was highly discouraged to place Codeine as an essential medication. [29] Not to mention, it was further discouraged in 2011 when Codeine was removed from WHO essential medicine list for children, causing greater discussion of its use in adults. [29] Another article discusses the appropriateness of empirical dosing of different antibiotics on EMLs from multiple countries. [30] Using the top 31 priority bacterial infections as a comparator, results showed how broadening the antibiotic list and dose, would not only increase adherence to treating the infections. It would also address the antibiotic resistance complication in most bacterial infections. [30] This 2021 Cross-Sectional study, reviewed the antibiotics on the essential medicines list from 138 countries and assessed each countries national listing. The data showed that on average of the 44 essential antibiotic medications, 24 of them were accessible to the population, 5 of them considered on reserve, and 15 of them on WATCH using the AWaRe classification. [30]

Additionally, the use of therapeutic guidelines as a reference for the creation of the WHO Essential Medicine List has been used to provide consistency and alignment of treatment across the nation. [31] In the 2022 quantitative analysis study of cardiovascular medications, the data suggests how adopting a common formulary of combination therapy and specific types of drug classes improved patient adherence and cardiovascular outcomes within the region. [31] The study compared South Africa and 15 different South African Development Communities (SADC) essential medication lists of 2021 for cardiovascular medications. [31] Having majority of SADC lists aligned with the WHO essential medicine lists of South Africa, supports how implementing this into the national EML would provide greater accessibility and availability of CVD medications consistently throughout the nation. [31]

Implementation

While the WHO Essential Medicine Lists are a very valuable tool and integral to the country's medicine policy, there has not yet been enough effort to implement them. There are several factors that affect the adaptation and implementation of the WHO Essential Medicine Lists, as found by a 2022 qualitative evidence synthesis. [32] This study identified areas that need support in order to implement EML at a country level. [32] The lack of effort to implement WHO Essential medicines lists undermines the potential health benefits, exacerbates inequities in access, increase health costs and infrastructure.

Implementation of the WHO EML can be done with national medication selection committees that are able to operate with consultive mandates. [32] These committees also need very clear leadership, monitoring, and evaluations. Implementation of EMLs can be done efficiently if there is a form of a reimbursement process in order to help keep costs low. [32] Additionally, EMLs should have recommended clinical practices, such as listing necessary items, in order to make implementation of the list easy to do. For example, in the case of injectable medications, the EML should indicate that in addition to the medication a patient would also need an injection device and safety box. [33] Finally, there needs to be clear legislation and monitoring to make sure there is compliance. [32]

Society and Culture

Access to essential medicines are part of the Sustainable Development Goals, specifically goal 3.8. [34]

A number of organizations, which are global in scope, use the list to determine which medications they will supply. [7] Rather than strictly following the list, many nations refer to the essential medicines list as a guide for developing their own laws and regulations based on their own requirements. [35]

Ecuador, Ghana, The Philippines, South Africa, and Ukraine all include some mention of essential medicines or other health infrastructure that helps guide their economic policies on medicine pricing and benefit selection. [36] Especially in middle income countries where out-of-pocket spending on medications is common, health equity measures and economic policy helps evaluate the affordability of medications as well as the effects of public health legislation. [36]

Brazil had published their first EML called RENAME 13 years prior to the WHO's first essential medicines list. [37] RENAME included medicines that focused on safety, efficacy, and availability of medications, as well as Brazil's health priority of their population. The WHO EML encouraged Brazil to separate medications based on therapeutic classes, leading to both lists having the same format, despite different medications listed. The addition of the WHO's 2009 children's EML inspired Brazil to consider their own RENAME pediatric list. But limitations have caused Brazil to wait for further pediatric drug evidence within the country before finalizing their own children-specific EML. Challenges such as high prices and poor availability have impacted how citizens are actually able to obtain their medications, despite healthcare being a constitutional right in the country. [37]

China first published their own EML in 1982, with the current EML containing over 2,000 herbal, chemical, and biological medicines. [38] The Ministry of Health (MOH) consists of medical and economic experts that are divided into a consult and review group to develop their national medicines list. Provinces in China are able to form their own EML, but are not allowed to remove medicines already listed in the national EML. [39]

India first developed their National List of Essential Medicines (NLEM) back in 1996 with only a minimal amount of revisions. Evidence-based criteria is used to determine which medications to add or remove to the list. Clinicians, pharmacologists, pharmacists, etc. discuss and review the list where an open-house discussion is used to modify and finalize the NLEM. [40] However, poor medical supplies and staff with low health investments in implementations have caused people to go to private hospitals and clinics for treatment. And with a large variety on rural and urban populations throughout the country, healthcare services and general access are favored more towards the urban population. [40]

See also

Related Research Articles

<span class="mw-page-title-main">Budesonide/formoterol</span> Medication for asthma & chronic obstructive pulmonary disease

Budesonide/formoterol, sold under the brand name Symbicort among others, is a fixed-dose combination medication used in the management of asthma or chronic obstructive pulmonary disease (COPD). It contains budesonide, a steroid; and formoterol, a long-acting β2-agonist (LABA). The product monograph does not support its use for sudden worsening or treatment of active bronchospasm. However, a 2020 review of the literature does support such use. It is used by breathing in the medication.

<span class="mw-page-title-main">Alteplase</span> Thrombolytic medication

Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction, pulmonary embolism associated with low blood pressure, and blocked central venous catheter. Alteplase is given by injection into a vein or artery. Alteplase is the same as the normal human plasminogen activator produced in vascular endothelial cells and is synthesized via recombinant DNA technology in Chinese hamster ovary cells (CHO). Alteplase causes the breakdown of a clot by inducing fibrinolysis.

<span class="mw-page-title-main">Primary health care</span> "Essential" health care key to securing universality by emphasizing community and equity

Primary health care (PHC) is a whole-of-society approach to effectively organise and strengthen national health systems to bring services for health and wellbeing closer to communities.

<span class="mw-page-title-main">Dacarbazine</span> Chemotherapy medication

Dacarbazine, also known as imidazole carboxamide and sold under the brand name DTIC-Dome, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma. For Hodgkin's lymphoma it is often used together with vinblastine, bleomycin, and doxorubicin. It is given by injection into a vein.

<span class="mw-page-title-main">Homatropine</span> Medication

Homatropine is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic, and as a mydriatic.

<span class="mw-page-title-main">Health policy</span> Policy area that deals with the health system of a country or other organization

Health policy can be defined as the "decisions, plans, and actions that are undertaken to achieve specific healthcare goals within a society". According to the World Health Organization, an explicit health policy can achieve several things: it defines a vision for the future; it outlines priorities and the expected roles of different groups; and it builds consensus and informs people.

Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. Also used to treat hepatitis C, it is no longer recommended due to poor efficacy and adverse side-effects. Subcutaneous injection is the preferred delivery method.

<span class="mw-page-title-main">Amodiaquine</span> Chemical compound

Amodiaquine (ADQ) is a medication used to treat malaria, including Plasmodium falciparum malaria when uncomplicated. It is recommended to be given with artesunate to reduce the risk of resistance. Due to the risk of rare but serious side effects, it is not generally recommended to prevent malaria. Though, the World Health Organization (WHO) in 2013 recommended use for seasonal preventive in children at high risk in combination with sulfadoxine and pyrimethamine.

Medication costs, also known as drug costs are a common health care cost for many people and health care systems. Prescription costs are the costs to the end consumer. Medication costs are influenced by multiple factors such as patents, stakeholder influence, and marketing expenses. A number of countries including Canada, parts of Europe, and Brazil use external reference pricing as a means to compare drug prices and to determine a base price for a particular medication. Other countries use pharmacoeconomics, which looks at the cost/benefit of a product in terms of quality of life, alternative treatments, and cost reduction or avoidance in other parts of the health care system. Structures like the UK's National Institute for Health and Clinical Excellence and to a lesser extent Canada's Common Drug Review evaluate products in this way.

A formulary is a list of pharmaceutical drugs, often decided upon by a group of people, for various reasons such as insurance coverage or use at a medical facility. Traditionally, a formulary contained a collection of formulas for the compounding and testing of medication. Today, the main function of a prescription formulary is to specify particular medications that are approved to be prescribed at a particular hospital, in a particular health system, or under a particular health insurance policy. The development of prescription formularies is based on evaluations of efficacy, safety, and cost-effectiveness of drugs.

<span class="mw-page-title-main">Dolutegravir</span> Chemical compound

Dolutegravir (DTG), sold under the brand name Tivicay, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. It is taken by mouth.

The Medicines Patent Pool (MPP) is a Unitaid-backed international organisation founded in July 2010, based in Geneva, Switzerland. Its public health driven business model aims to lower the prices of HIV, tuberculosis and hepatitis C medicines and facilitate the development of better-adapted HIV treatments through voluntary licensing and patent pooling. Its goal is to improve access to affordable and appropriate HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries (LMIC). In May 2020, the MPP become an implementing partner of the WHO's Covid-19 Technology Access Pool (C-TAP).

Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing illness, death and transmission was first proposed in 2000 by Garnett et al. The term is often used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to prevent illness, death and transmission. Although some experts narrow this to only include preventing infections, treatment prevents illnesses such as tuberculosis and has been shown to prevent death. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans. When taken correctly, ART is able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.

EMDEX is the most commonly used reference source of drug and therapeutic information by healthcare professionals in Nigeria. It was first published in 1991 as Nigeria's Essential Drugs (NED) Guide.
EMDEX drug information contents, arrangements, and therapeutic recommendations are supported by several references and clinical guidelines notably WHO Model Formulary, WHO ATC Classification System, Nigeria's Essential Medicines List, and Standard Treatment Guidelines, etc. The information is regularly reviewed and updated by a select team of healthcare practitioners and academics.
The central objective of EMDEX has been to promote the rational use of medicines through the provision of independent drug information, and the use of clinical guidelines and essential medicines list. It is the largest and most up-to-date source of information on drug products approved for use in Nigeria by NAFDAC .
The use of EMDEX as a reference drug manual is endorsed by the Pharmacists Council of Nigeria, the Nursing & Midwifery Council of Nigeria, and major health institutions. It is used both within and outside Nigeria by physicians, dentists, pharmacists, nurse practitioners, and auxiliary health workers at all levels of healthcare delivery. These healthcare providers rely on EMDEX for accuracy and completeness of drug information namely indications, contra-indications, precautions or warnings, adverse effects, dosages, and drug use in special populations like children, elderly, pregnancy & lactation.
EMDEX publications are also in the syllabus of various colleges & schools of medicine, pharmacy & nursing.

In global health, priority-setting is a term used for the process and strategy of deciding which health interventions to carry out. Priority-setting can be conducted at the disease level, the overall strategy level, research level, or other levels.

Access to medicines refers to the reasonable ability for people to get needed medicines required to achieve health. Such access is deemed to be part of the right to health as supported by international law since 1946.

Drug recycling, also referred to as medication redispensing or medication re-use, is the idea that health care organizations or patients with unused drugs can transfer them in a safe and appropriate way to another patient in need. The purpose of such a program is reducing medication waste, thereby saving healthcare costs, enlarging medications’ availability and alleviating the environmental burden of medication.

External reference pricing (ERP), also known as international reference pricing, is the practice of regulating the price of a medication in one country, by comparing with the price in a "basket" of other reference countries. It contrasts with internal reference pricing, where the price of one drug is compared to the domestic price of therapeutically related drugs, and with cost-plus pricing, where the price involves negotiating an acceptable markup to the unit cost to develop and produce.

The WHO AWaRe Classification is a method to categorize antibiotics into three groups in an effort to improve appropriate antibiotic use. The classification is based, in part, on the risk of developing antibiotic resistance and their importance to medicine. It does not reflect effectiveness or strength. It is accompanied by a book that outlines which and how to use antibiotics in 34 common infections.

References

  1. 1 2 "Essential medicines". World Health Organization (WHO). Archived from the original on October 2, 2008. Retrieved 20 January 2017.
  2. ↑ "The Selection and Use of Essential Medicines (ss 4.2)". Essential Medicines and Health Products Information Portal. WHO Technical Report Series. World Health Organization (WHO). 2003. p. 132. Archived from the original on February 1, 2014.
  3. ↑ Organization WH (2019). "World Health Organization model list of essential medicines: 21st list 2019". World Health Organization. hdl: 10665/325771 .
  4. 1 2 Organization WH (2019). "World Health Organization model list of essential medicines for children: 7th list 2019". World Health Organization. hdl: 10665/325772 .
  5. ↑ "The selection and use of essential medicines: report of the WHO Expert Committee on selection and use of Essential Medicine" (PDF). World Health Organization. 2021.
  6. ↑ Hwang TJ, Kesselheim AS, Vokinger KN (2022-11-08). "Reforming the World Health Organization's Essential Medicines List: Essential but Unaffordable". JAMA. 328 (18): 1807–1808. doi:10.1001/jama.2022.19459. ISSN   1538-3598. PMID   36279114.
  7. 1 2 3 4 5 6 Seyberth HW, Rane A, Schwab M (2011). Pediatric Clinical Pharmacology. Springer Science & Business Media. p. 358. ISBN   978-3-642-20195-0.
  8. ↑ "Essential Medicines: a balancing act". The Lancet Haematology. December 2019.
  9. ↑ "Action programme on essential drugs: progress report by the Director-General". World Health Assembly. 32. World Health Organization. 2019. hdl: 10665/153132 .
  10. ↑ "Trade, foreign policy, diplomacy and health". Essential Medicines. World Health Organization (WHO). Dec 6, 2010. Archived from the original on August 6, 2004.
  11. ↑ Kar SS, Pradhan HS, Mohanta GP (January 2010). "Concept of essential medicines and rational use in public health". Indian Journal of Community Medicine. 35 (1): 10–13. doi: 10.4103/0970-0218.62546 . PMC   2888334 . PMID   20606912.
  12. 1 2 Zhang M (April 25, 2023). "Availability of essential medicines, progress and regional distribution in China: a systematic review and meta-analysis". Frontiers in Public Health. 11. doi: 10.3389/fpubh.2023.1149838 . PMC   10167309 . PMID   37181691.
  13. 1 2 3 Evans DB, Hsu J, Boerma T (2013-08-01). "Universal health coverage and universal access". Bulletin of the World Health Organization. 91 (8): 546–546A. doi:10.2471/BLT.13.125450 (inactive 5 December 2024). ISSN   0042-9686. PMC   3738317 . PMID   23940398.{{cite journal}}: CS1 maint: DOI inactive as of December 2024 (link)
  14. ↑ Hoppu K (June 2017). "Essential Medicines for Children". Clinical Pharmacology and Therapeutics. 101 (6): 718–720. doi:10.1002/cpt.661. PMID   28182281. S2CID   23873145.
  15. ↑ Perehudoff K (December 2020). "Universal access to essential medicines as part of the right to health: a cross-national comparison of national laws, medicines policies, and health system indicators". Global Health Action. 13 (1): 1699342. doi:10.1080/16549716.2019.1699342. PMC   7605313 . PMID   33131456.
  16. ↑ Charles O, Onakpoya I, Benipal S, Woods H, Bali A, Aronson JK, et al. (2019). "Withdrawn medicines included in the essential medicines lists of 136 countries". PLOS ONE. 14 (12): e0225429. Bibcode:2019PLoSO..1425429C. doi: 10.1371/journal.pone.0225429 . PMC   6887519 . PMID   31791048.
  17. ↑ Vargas-Pelaez CM, Rover MR, Leite SN, Buenaventura FR, Farias MR (November 2014). "Right to Health, essential medicines, and lawsuits for access to medicines-A scoping study". Social Science & Medicine. 121: 48–55. doi:10.1016/j.socscimed.2014.08.042. PMID   25306409.
  18. ↑ Serafini M, Cargnin S, Massarotti A, Pirali T, Genazzani AA (24 September 2020). "Essential Medicinal Chemistry of Essential Medicines". Journal of Medicinal Chemistry. 63 (18): 10170–10187. doi:10.1021/acs.jmedchem.0c00415. ISSN   0022-2623. PMC   8007110 . PMID   32352778.
  19. ↑ Zacher M, Keefe TJ (2008). The Politics of Global Health Governance: United by Contagion. Springer. p. 107. ISBN   978-0-230-61195-5.
  20. ↑ "Equitable access to essential medicines: a framework for collective action". World Health Organization. 2004.
  21. ↑ Laing R, Waning B, Gray A, Ford N, 't Hoen E (May 2003). "25 years of the WHO essential medicines lists: progress and challenges". Lancet. 361 (9370): 1723–1729. doi:10.1016/S0140-6736(03)13375-2. hdl: 10144/28005 . PMID   12767751.
  22. 1 2 Mahmić-Kaknjo M, Jeličić-Kadić A, Utrobičić A, Chan K, Bero L, Marušić A (June 2018). "Essential medicines availability is still suboptimal in many countries: a scoping review" (PDF). Journal of Clinical Epidemiology. 98: 41–52. doi:10.1016/j.jclinepi.2018.02.006. PMID   29452222.
  23. 1 2 3 4 World Health Organization (2023). The selection and use of essential medicines 2023. Executive Summary of the report of the 24th WHO Expert Committee on Selection and Use of Essential Medicines. Geneva: World Health Organization. hdl: 10665/371291 . WHO/MVP/EMP/IAU/2023.01. License: CC BY-NC-SA 3.0 IGO.
  24. ↑ Bazargani YT, Ewen M, De Boer A, Leufkens H, Teeuwisse A (February 12, 2014). "Essential Medicines Are More Available than Other Medicines around the Globe". PLOS ONE. 9 (2): e87576. Bibcode:2014PLoSO...987576B. doi: 10.1371/journal.pone.0087576 . PMC   3922716 . PMID   24533058.
  25. 1 2 Gray NJ, Chanoine JP, Farmer MY, Jarvis JD, Armstrong K, Barr RD, et al. (1 November 2019). "NCDs and the WHO Essential Medicines Lists: children need universal health coverage too". The Lancet Child & Adolescent Health. 3 (11): 756–757. doi:10.1016/S2352-4642(19)30294-9. ISSN   2352-4642. PMID   31537467 . Retrieved 30 July 2024.
  26. ↑ Gitanjali B (January 2011). "Essential medicines for children: Should we focus on a priority list of medicines for the present?". Journal of Pharmacology & Pharmacotherapeutics. 2 (1): 1–2. doi: 10.4103/0976-500X.77073 . PMC   3117561 . PMID   21701637.
  27. ↑ Nsabagasani X, Ogwal-Okeng J, Mbonye A, Ssengooba F, Nantanda R, Muyinda H, et al. (2015-01-31). "The "child size medicines" concept: policy provisions in Uganda". Journal of Pharmaceutical Policy and Practice. 8 (1): 2. doi: 10.1186/s40545-015-0025-7 . PMC   4342089 . PMID   25815197.
  28. ↑ Orubu E (2022). "WHO essential medicines for children 2011-2019: age-appropriateness of enteral formulations". Archives of Disease in Childhood. 107 (4): 317–322. doi:10.1136/archdischild-2021-321831. PMID   34479858 . Retrieved July 29, 2024.
  29. 1 2 3 4 Singu B, Verbeeck RK (2021). "Should Codeine Still be Considered a WHO Essential Medicine?". Journal of Pharmacy & Pharmaceutical Sciences. 24: 329–335. doi: 10.18433/jpps31639 . ISSN   1482-1826. PMID   34192509.
  30. 1 2 3 Adekoya I, Maraj D, Steiner L, Yaphe H, Moja L, Magrini N, et al. (2021). "Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study". The Lancet. Infectious Diseases. 21 (10): 1429–1440. doi:10.1016/S1473-3099(20)30854-9. ISSN   1474-4457. PMID   34332706.
  31. 1 2 3 4 Naicker I (2022). "A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list". The Lancet. Infectious Diseases. 15 (1): 97. doi: 10.1186/s40545-022-00494-0 . PMC   9733348 . PMID   36482421.
  32. 1 2 3 4 5 Peacocke EF, Myhre SL, Foss HS, Gopinathan U (March 2022). "National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis". PLOS Medicine. 19 (3): e1003944. doi: 10.1371/journal.pmed.1003944 . PMC   8956172 . PMID   35275938.
  33. ↑ Logez SM, Hutin YJ, Holloway K, Gray R, Hogerzeil HV (October 2004). "Could the WHO Model List of Essential Medicines Do More for the Safe and Appropriate Use of Injections?". The Journal of Clinical Pharmacology. 44 (10): 1106–1113. doi:10.1177/0091270004268410. ISSN   0091-2700. PMID   15342611 . Retrieved 1 August 2024.
  34. ↑ Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. (January 2017). "Essential medicines for universal health coverage". Lancet. 389 (10067): 403–476. doi:10.1016/S0140-6736(16)31599-9. PMC   7159295 . PMID   27832874.
  35. ↑ Perehudoff K, Demchenko I, Alexandrov NV, Brutsaert D, Ackon A, Durán CE, et al. (December 2020). "Essential Medicines in Universal Health Coverage: A Scoping Review of Public Health Law Interventions and How They Are Measured in Five Middle-Income Countries". International Journal of Environmental Research and Public Health. 17 (24): 9524. doi: 10.3390/ijerph17249524 . PMC   7765934 . PMID   33353250.
  36. 1 2 Perehudoff K, Demchenko I, Alexandrov NV, Brutsaert D, Ackon A, Durán CE, et al. (2020-12-18). "Essential Medicines in Universal Health Coverage: A Scoping Review of Public Health Law Interventions and How They Are Measured in Five Middle-Income Countries". International Journal of Environmental Research and Public Health. 17 (24): 9524. doi: 10.3390/ijerph17249524 . ISSN   1660-4601. PMC   7765934 . PMID   33353250.
  37. 1 2 Coelho HL, Rey LC, de Medeiros MS, Barbosa RA, da Cruz Fonseca SG, da Costa PQ (2013-03-01). "A critical comparison between the World Health Organization list of essential medicines for children and the Brazilian list of essential medicines (Rename)". Jornal de Pediatria (Versão em Português). 89 (2): 171–178. doi:10.1016/j.jpedp.2012.08.012. ISSN   2255-5536.
  38. ↑ Barber SL, Huang B, Santoso B, Laing R, Paris V, Wu C (2013). "The reform of the essential medicines system in China: a comprehensive approach to universal coverage" (PDF). Journal of Global Health. 3 (1): 010303. doi:10.7189/jogh.03.010303. ISSN   2047-2978. PMC   3700034 . PMID   23826503.
  39. ↑ Wang D, Zhang X (2011-04-10). "The selection of essential medicines in China: progress and the way forward". Southern Med Review. 4 (1). doi:10.5655/smr.v4i1.71. ISSN   1174-2704.
  40. 1 2 "National List of Essential Medicines of India, NLEM 2011". WHO. 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.